• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Silo Pharma Announces Initial Investment in Ethereum and Solana under Cryptocurrency Treasury Strategy

    9/16/25 8:11:00 AM ET
    $SILO
    Apparel
    Consumer Discretionary
    Get the next $SILO alert in real time by email

    Strategic capital deployment advances Company's blockchain treasury model and biopharma development initiatives

    SARASOTA, FL, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced its initial purchases of crypto tokens under its recently announced cryptocurrency treasury strategy targeting multi-chain asset growth.

    The Company's acquisition of Ethereum (ETH) and Solana (SOL) tokens marks the first step toward incorporating cryptocurrency into its treasury holdings and lays the foundation for Silo's broader blockchain and real world asset (RWA) tokenization initiatives. The investment underscores the Company's belief in the long-term value of digital assets and the potential of underlying blockchain technology to shape the future of biotechnology.

    "Our initial purchases of Ethereum and Solana reflect our deep conviction in decentralized blockchain and decentralized finance as the leading smart contract platforms," said Eric Weisblum, CEO of Silo. "We have begun staking the tokens for revenue generation and capital appreciation to further strengthen our financial position and support the clinical progression of our biopharmaceutical assets."

    Silo's comprehensive digital assets strategy aligns with the accelerating adoption of digital assets by institutional investors and global enterprises, supported by a regulatory landscape that is steadily evolving to enable broader market acceptance

    About Silo Pharma

    Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. Its therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company's portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. Silo's research is conducted in collaboration with leading universities and laboratories. silopharma.com

    Forward-Looking Statements

    This news release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified using words "could", "believe", "anticipate", "intend", "estimate", "expect", "may", "continue", "predict", "potential", and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of Silo Pharma, Inc. ("Silo" or "the Company") to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company's technology platforms, retaining and expanding the Company's customer base, fluctuations in consumer spending on the Company's products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this press release, whether as a result of new information, future events, or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events except as required by law.

    Contact

    800-705-0120

    [email protected]



    Primary Logo

    Get the next $SILO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SILO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SILO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Weisblum Eric bought $4,329 worth of shares (10,000 units at $0.43), increasing direct ownership by 5% to 197,932 units (SEC Form 4)

    4 - Silo Pharma, Inc. (0001514183) (Issuer)

    5/28/25 4:30:42 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    SEC Form 4 filed by Director Linsley Wayne

    4 - Silo Pharma, Inc. (0001514183) (Issuer)

    5/27/25 7:03:42 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    SEC Form 4 filed by Director Munoz Kevin

    4 - Silo Pharma, Inc. (0001514183) (Issuer)

    5/27/25 7:03:16 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    $SILO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Silo Pharma Announces Closing of $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

    SARASOTA, FL, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 2,857,143 shares of common stock at a purchase price of $0.875 per share. In a concurrent private placement, the Company issued unregistered warrants to purchase up to 2,857,143 shares of common stock at an exercise price of $0.75 per share that are immediately exer

    10/1/25 4:20:00 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    Silo Pharma Announces $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

    SARASOTA, FL, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that it has entered into definitive agreements for the purchase and sale of 2,857,143 shares of common stock at a purchase price of $0.875 per share in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company will issue unregistered warrants to purchase up to 2,857,143 shares of common stock at an exercise price of $0.75 per share that wil

    9/30/25 8:02:00 AM ET
    $SILO
    Apparel
    Consumer Discretionary

    Silo Pharma Updates Strategic Agreement with Fireblocks to Secure Crypto Treasury Management

    Fireblocks is a globally recognized leader in the digital assets space, facilitating the secure transfer of more than $10 trillion to date SARASOTA, FL, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ: SILO) ("Silo" or "the Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, announced that it has begun implementing its strategic agreement with Fireblocks, an enterprise platform for secure digital asset custody, settlement, trading operations, and stablecoin payments, to provide institutional-grade infrastructure for its crypto treasury management platform\. Eric Weisblum, CEO of Silo, commented, "Fireblocks brings unmatched ex

    9/29/25 2:30:00 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    $SILO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Weisblum Eric bought $4,329 worth of shares (10,000 units at $0.43), increasing direct ownership by 5% to 197,932 units (SEC Form 4)

    4 - Silo Pharma, Inc. (0001514183) (Issuer)

    5/28/25 4:30:42 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    CEO and President Weisblum Eric bought $2,097 worth of shares (2,500 units at $0.84), increasing direct ownership by 1% to 187,932 units (SEC Form 4)

    4 - Silo Pharma, Inc. (0001514183) (Issuer)

    12/16/24 5:00:06 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    CEO and President Weisblum Eric bought $4,625 worth of shares (5,000 units at $0.93), increasing direct ownership by 3% to 185,432 units (SEC Form 4)

    4 - Silo Pharma, Inc. (0001514183) (Issuer)

    11/22/24 4:16:10 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    $SILO
    SEC Filings

    View All

    Silo Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

    8-K - Silo Pharma, Inc. (0001514183) (Filer)

    10/1/25 4:30:26 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    SEC Form 424B5 filed by Silo Pharma Inc.

    424B5 - Silo Pharma, Inc. (0001514183) (Filer)

    10/1/25 8:51:32 AM ET
    $SILO
    Apparel
    Consumer Discretionary

    SEC Form DEFA14A filed by Silo Pharma Inc.

    DEFA14A - Silo Pharma, Inc. (0001514183) (Filer)

    9/5/25 5:09:03 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    $SILO
    Leadership Updates

    Live Leadership Updates

    View All

    Silo Pharma Appoints Crypto Infrastructure Pioneer Corwin Yu to Launch Institutional Bitcoin, Ethereum and Solana Treasury Platform

    Targeting Multi-Chain Digital Asset Growth and Decentralized Finance (DeFi) Integration SARASOTA, FL, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO), today announced the launch of a cryptocurrency treasury strategy which is expected to focus on leading digital assets, including Bitcoin, Ethereum, and Solana. The Company intends to make opportunistic purchases of digital currencies following launch and to leverage staking to generate yield while also focusing on capital preservation and token appreciation. Expanded implementation of this strategy is anticipated to be based on available capital and market conditions. Silo has appointed digital asset tech pioneer, Corwin

    8/5/25 8:32:00 AM ET
    $SILO
    Apparel
    Consumer Discretionary

    $SILO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Silo Pharma Inc.

    SC 13G - Silo Pharma, Inc. (0001514183) (Subject)

    7/26/24 4:17:36 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    SEC Form SC 13G filed by Silo Pharma Inc.

    SC 13G - Silo Pharma, Inc. (0001514183) (Subject)

    6/13/24 5:08:53 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    SEC Form SC 13G/A filed by Silo Pharma Inc. (Amendment)

    SC 13G/A - Silo Pharma, Inc. (0001514183) (Subject)

    1/25/24 5:27:04 PM ET
    $SILO
    Apparel
    Consumer Discretionary